An interventional study of Octacosanol and Placebo in Oxidative Stress and Dyslipidemias, sponsored by Kosin University. Completed at 1 site in United States. Open to male participants aged 17 Years to 19 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-10.
Sponsored by Kosin University · Not applicable, Interventional, and Treatment
Taekwondo players undergo rapid reductions of body weight prior to their competition in order to gain a size advantage over the opponent. However, these large weight changes with concomitant high intensity exercise training induce poor lipid profiles and high levels of oxidative stress, which can be detrimental to health and sports performance. Therefore, the purpose of this study was to investigate the ability of the nutritional supplement octacosanol to combat the physiological detriments that can occur from these rapid weight changes paired with high intensity exercise training.
Athletes that participate in weight division sports such as taekwondo, boxing, judo, and wrestling regularly reduce their body weight severely prior to competition in order to gain a size advantage over the opponent while simultaneously meeting their weight division requirements. In general, athletes have acute weight loss of 4-7 kg within 3-4 days of competition, while longer periods of more gradual weight loss of 15-22 kg lasting 3-4 weeks. Although this kind of extreme weight loss can induce metabolic dysfunction, it is repeatedly performed by athletes of weight division sports in order to acquire a more advantageous condition for play. Furthermore, athletes participating in matches tend to obtain excessive weights compared to their weight division during the offseason in order to lift heavier weights during training, and then rapidly lose that weight over a short period of time prior to competition, resulting in the deterioration of physiological function and possibly sports performance.
Rapid weight loss with high intensity exercise training also increases oxygen free radical production to a point that exceeds the defense mechanism of antioxidant enzymes in the body and ultimately results in damage to the cells, specifically, the lipid peroxidation of cell membranes. Not only does this decrease physiological function, but sports performance can also decrease as oxidative stress increases due to an interference in metabolic activity, a reduction in vascular function and an increase in systemic inflammation. Octacosanol, a straight-chain, high-molecular-weight, primary aliphatic alcohol minimally contained in the germinal disks of rice bran, wheat and sugar cane, may be able to prevent these deteriorations as it has been shown to provide various health benefits. In fact, previous studies reported that pre-exercise octacosanol intake contributed to enhanced muscular strength, muscular endurance and oxygen transport ability. Additionally, octacosanol supplementation has been shown to improve cardiovascular endurance and heart function in patients with peripheral artery disease, improve levels of low-density and high-density lipoprotein-cholesterol in patients with hypercholesterolemia, and increase glycogen accumulation in mice9. However, the potential beneficial effects of octacosanol intake for reducing free radical production and preventing detrimental physiological function from excessive weight loss with high intensity exercise has not been examined. Thus, the purpose of this study was to investigate the effects of octacosanol supplementation during acute weight loss with high-intensity exercise training on lipid profiles and markers of oxidative stress in taekwondo players.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 26 is below the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Kosin University is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
Dietary Supplement: Octacosanol
A placebo pill was taken twice daily in replacement of the octacosanol supplement
Dietary Supplement: Placebo
One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
Triglycerides
Plasma triglyceride levels
Time frame: 6 days
Total Cholesterol
Plasma total cholesterol levels
Time frame: 6 days
High-density Lipoprotein
Plasma levels of high-density lipoprotein
Time frame: 6 days
Low-density Lipoprotein
Plasma levels of low-density lipoprotein
Time frame: 6 days
Malondialdehyde
Plasma levels of malondialdehyde
Time frame: 6 days
Superoxide Dismutase
Plasma levels of superoxide dismutase
Time frame: 6 days
Glutathione Peroxidase
Plasma levels of glutathione peroxidase
Time frame: 6 days
| Milestone | Octacosanol | Placebo |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 13 |
| Not completed | 0 | 0 |
Plasma triglyceride levels
| mg/dL | Octacosanol | Placebo |
|---|---|---|
| Triglycerides | 34.9 ± 7.8 | 110 ± 8.1 |
Plasma total cholesterol levels
| mg/dL | Octacosanol | Placebo |
|---|---|---|
| Total Cholesterol | 164 ± 12.8 | 173.5 ± 16.1 |
Plasma levels of high-density lipoprotein
| mg/dL | Octacosanol | Placebo |
|---|---|---|
| High-density Lipoprotein | 71 ± 4.4 | 49.2 ± 2.6 |
Plasma levels of low-density lipoprotein
| mg/dL | Octacosanol | Placebo |
|---|---|---|
| Low-density Lipoprotein | 92.6 ± 8.1 | 114.9 ± 10.8 |
Plasma levels of malondialdehyde
| mmol/mL | Octacosanol | Placebo |
|---|---|---|
| Malondialdehyde | 0.25 ± 0.1 | 0.93 ± 0.12 |
Plasma levels of superoxide dismutase
| U/gHb | Octacosanol | Placebo |
|---|---|---|
| Superoxide Dismutase | 1450 ± 138.9 | 1010 ± 150.1 |
Plasma levels of glutathione peroxidase
| U/gHb | Octacosanol | Placebo |
|---|---|---|
| Glutathione Peroxidase | 66.9 ± 10.8 | 47.1 ± 9.7 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octacosanol | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Placebo | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Age, Continuous(years) | Octacosanol | Placebo | Total |
|---|---|---|---|
| Mean | 18 ± 1 | 18 ± 1 | 18 ± 1.3 |
| Sex: Female, Male(Participants) | Octacosanol | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 13 | 13 | 26 |
| Race (NIH/OMB)(Participants) | Octacosanol | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 13 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Octacosanol | Placebo | Total |
|---|---|---|---|
| South Korea | 13 | 13 | 26 |
| Height(cm) | Octacosanol | Placebo | Total |
|---|---|---|---|
| Mean | 174.7 ± 1.4 | 173.9 ± 6.3 | 174.3 ± 3.9 |
| Weight(kg) | Octacosanol | Placebo | Total |
|---|---|---|---|
| Mean | 66.9 ± 6.7 | 66.7 ± 5.7 | 66.8 ± 6.2 |
| Body fat(percentage of body fat) | Octacosanol | Placebo | Total |
|---|---|---|---|
| Mean | 8 ± 2 | 8 ± 2 | 8 ± 2.4 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kosin University